Helix BioPharma Corp., a clinical-stage oncology company, announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. The company stated these additions strengthen its executive leadership as it prepares for a planned U.S. securities exchange listing and advances L-DOS47 into the next stage of clinical development through the LDOS007 study, a Phase IB/Randomized Phase II trial in first-line non-small cell lung cancer (NSCLC).
“The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix’s growth.”
Mehrling further noted that with the preparation of a base shelf prospectus underway and the auditor review of second-quarter financials completed, the company is executing on a clear capital markets roadmap. He highlighted that Middleton and Browning are exceptional additions, with Middleton bringing decades of experience in legal and governance challenges for growing life sciences companies, and Browning having successfully led complex global oncology programs.
Helen Middleton, a qualified life sciences lawyer and registered clinical pharmacist with over 30 years of experience, has held senior legal roles at firms including Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. Most recently, she served as Legal Consultant to Kyowa Kirin International. As General Counsel, she will oversee Helix’s legal affairs, governance, compliance, and strategic transactions.
David Browning brings over 30 years of experience leading global clinical development programs, having overseen more than 30 Phase I-III clinical studies across various oncology indications and therapeutic modalities. He previously built and led global oncology clinical operations teams across multiple regions. As Vice President of Clinical Operations, he will lead operational planning and execution for Helix’s clinical programs, including LDOS007.
These appointments are part of Helix’s strategy to build infrastructure for its next phase of growth. The company’s pipeline includes L-DOS47, a Tumor Defense Breaker antibody-enzyme conjugate targeting CEACAM6-expressing tumors, along with pre-IND candidates LEUMUNA and GEMCEDA. Helix is listed on the TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). More information is available at https://www.helixbiopharma.com/.
